Zacks Investment Research on MSN

BDTX: What silevertinib data say about EGFR NSCLC upside

Black Diamond Therapeutics, Inc. BDTX is building its equity story around a single, high-leverage asset: silevertinib, a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) ...
Zacks Investment Research on MSN

Black Diamond stock: Weighing catalysts vs. concentration

Black Diamond Therapeutics, Inc. BDTX offers a high-leverage oncology setup built around one primary value driver: silevertinib, a brain-penetrant, fourth-generation epidermal growth factor receptor ...
Managed Healthcare Executive

Setidegrasib shows early promise in KRAS G12D-mutated lung and pancreatic cancers

“Setidegrasib is the first drug in this KRAS degrader class targeting KRAS G12D in solid tumors,” lead investigator Wungki ...
Healio

Zongertinib a ‘breakthrough’ first-line treatment for NSCLC with HER2 mutations

Zongertinib provided substantial clinical benefit for patients with advanced or metastatic HER2-mutant advanced non-small cell lung cancer, surpassing the historical standard of care efficacy for this ...
Targeted Oncology

New Drug Application Submitted for Neladalkib in Advanced ALK+ NSCLC

Nuvalent has submitted an NDA to the FDA for neladalkib, a brain-penetrant ALK-selective TKI for pretreated advanced ...
Pharmabiz

China NMPA approves Dizal's sunvozertinib to treat locally advanced or metastatic NSCLC with EGFR Exon20ins mutations

China NMPA approves Dizal's sunvozertinib to treat locally advanced or metastatic NSCLC with EGFR Exon20ins mutations: Shanghai Thursday, August 24, 2023, 18:00 Hrs [IST] Dizal, a ...
CURE

Tagrisso Plus Chemo Extends Time Without Cancer Growth in NSCLC

Tagrisso combined with chemotherapy improved how long patients with EGFR- and TP53-mutant NSCLC lived without their cancer worsening compared with Tagrisso alone. At the 2026 European Lung Cancer ...
Medscape

Gefitinib Yields Superior Outcomes vs Chemotherapy in EGFR-Mutation-Positive NSCLC

Several reports have noted that individuals with NSCLC whose tumors are documented to contain a mutation in the EGFR receptor have a substantially greater chance of responding to small-molecule ...
ascopubs.org

Utilizing TP53 mutation status and initial disease burden at presentation to risk-stratify patients with advanced EGFR-mutated NSCLC treated with osimertinib.

Next generation sequencing (NGS) of malignant effusions and comparison to blood liquid biopsy (ctDNA): A community experience. Celecoxib vs placebo in combination with chemotherapy for non-small cell ...
Nasdaq

ArriVent BioPharma Reports Promising 16-Month Median Progression-Free Survival for Firmonertinib in First-Line NSCLC Patients with EGFR PACC Mutations

16.0 months median progression-free survival (mPFS) with firmonertinib indicates strong efficacy in first-line patients with EGFR PACC mutant non-small cell lung cancer (NSCLC). Robust central nervous ...
ascopubs.org

Genomic landscape of NSCLC with no targetable driver mutation among different races: An exploratory analysis of the AACR Project GENIE Database.

A window of opportunity study for preoperative brigatinib in resectable anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC): WILDERNESS trial. This is an ASCO Meeting Abstract ...
Seeking Alpha

Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the ...

Real-world data demonstrate non-classical mutations are present in 20-30% of all patients with EGFRm NSCLC Emerging data show non-classical EGFR mutations can be co-expressed with the classical L858R ...